Exhibit 99.1

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

•Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology

•Treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis, seven patients with lupus nephritis, and four patients with multiple sclerosis

•Strong balance sheet, bolstered by recent public offering

EMERYVILLE, Calif., May 14, 2024 – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2024.

“We continue to build momentum in the clinical development of our lead product candidate, KYV-101, as we seek to bring autoimmune CAR T-cell therapies to more patients across both the US and Europe,” said Peter Maag, Chief Executive Officer of Kyverna. “We are excited to build on our leadership position in 2024 and continue to execute diligently on our promise to bring hope to patients living with autoimmune disorders.”

First Quarter 2024 and Recent Business Highlights

•Advanced clinical development of KYV-101, our proprietary CD19 chimeric antigen receptor (CAR) T-cell therapy for autoimmunity, in clinical trials and investigator-initiated trials across the US and Europe

•Treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis, seven patients with lupus nephritis, and four patients with multiple sclerosis

•Published early clinical data showing first-in-disease use of KYV-101 in patients with refractory progressive multiple sclerosis

•KYV-101 granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of myasthenia gravis

•Progressed the global KYSA clinical trial program in multiple indications across rheumatology and neurology: Phase 1/2 trials in lupus nephritis (KYSA-1 and KYSA-3), a Phase 1/2 trial in systemic sclerosis (KYSA-5), a Phase 2 trial in myasthenia gravis (KYSA-6), and a Phase 2 trial in multiple sclerosis (KYSA-7)

•Strengthened balance sheet with approximately $366.9 million in gross proceeds from our initial public offering in February 2024

Upcoming Milestones

•Interim patient data releases and symposia at EULAR in second quarter of 2024, ECTRIMS in third quarter of 2024 and ACR in fourth quarter of 2024

•Regulatory progress in rheumatology and neurology in the US and Europe

•Ongoing progress with Ingenui-T, our manufacturing process designed to improve patient experience and manufacturing efficiencies

•Updates on KYV-201, our allogeneic CD19 CAR T-cell product candidate

Financial Results for the Quarter Ended March 31, 2024

For the quarter ended March 31, 2024, the company reported a net loss of $26.7 million, or a net loss per common share of $1.12, compared to a net loss of $11.1 million, or a net loss per common share of $12.10, for the same period in 2023.

During the quarter ended March 31, 2024, net cash used in operating activities was $25.5 million, compared to $11.5 million for the same period in 2023.

Kyverna reported $369.8 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2024, inclusive of approximately $336.2 million in net proceeds raised from its initial public offering that was completed in February 2024, after deducting underwriting discounts and commissions and other offering costs.

About Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit www.kyvernatx.com.

Forward-looking Statements

This press release contains forward looking statements that are based on management’s beliefs and assumptions and on information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other than statements of historical facts contained in this press release are forward looking statements. Forward looking statements include, but are not limited to, statements concerning: the Company’s future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies and named patient activities, ongoing clinical trials, research and development costs, plans for manufacturing, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 26, 2024 and any subsequent Quarterly Reports on Form 10-Q filed by the Company. Actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. When evaluating Kyverna’s business and prospects, careful consideration should be given to these risks and uncertainties. These statements speak only as of the date of this press release, and Kyverna undertakes no obligation to update or revise these statements.

For more information, please contact:

Investor Contact:

George Thampy

Kyverna Therapeutics

InvestorRelations@kyvernatx.com

Media Contact:

Consort Partners for Kyverna

kyvernatx@consortpartners.com

Kyverna Therapeutics, Inc.

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(unaudited)

	Three Months Ended March 31,
	2024			2023
Operating expenses
Research and development	$	22,476		$	8,711
General and administrative		6,882			2,734
Total operating expenses		29,358			11,445
Loss from operations		(29,358	)		(11,445	)
Interest income		2,735			349
Interest expense		(44	)		(44	)
Other expense, net		(26	)		(3	)
Total other income, net		2,665			302
Net loss		(26,693	)		(11,143	)
Other comprehensive gain (loss)
Unrealized gain (loss) on available-for-sale marketable securities, net		(5	)		18
Total other comprehensive gain (loss)		(5	)		18
Net loss and other comprehensive loss	$	(26,698	)	$	(11,125	)
Net loss per share attributable to common stockholders, basic and diluted	$	(1.12	)	$	(12.10	)
Weighted-average shares of common stock outstanding, basic and diluted		23,754,062			921,260

Kyverna Therapeutics, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)

(unaudited)

	March 31,			December 31,
	2024			2023
Assets
Current assets
Cash and cash equivalents	$	224,287		$	34,647
Available-for-sale marketable securities		145,507			22,896
Prepaid expenses and other current assets		5,694			3,121
Total current assets		375,488			60,664
Restricted cash		570			565
Property and equipment, net		2,714			2,326
Operating lease right-of-use assets		8,486			6,494
Finance lease right-of-use assets		1,552			1,790
Other non-current assets		1,174			3,356
Total assets	$	389,984		$	75,195
Liabilities, redeemable convertible preferred stock and stockholders’   equity (deficit)
Current liabilities
Accounts payable	$	7,451		$	4,358
Accrued compensation		1,363			2,812
Accrued license expense – related party		6,250			6,250
Other accrued expenses and current liabilities		3,083			3,519
Operating lease liabilities, short-term portion		2,739			1,964
Finance lease liabilities, short-term portion		979			956
Total current liabilities		21,865			19,859
Operating lease liabilities, net of short-term portion		6,461			5,238
Finance lease liabilities, net of short-term portion		667			921
Total liabilities		28,993			26,018
Commitments and contingencies
Redeemable convertible preferred stock, no par value; no shares authorized, issued and outstanding as of March 31, 2024; $0.00001 par value, 114,556,997 shares authorized as of December 31, 2023; 114,556,997 shares issued and outstanding as of December 31, 2023; liquidation preference of $181,250 as of December 31, 2023		—			180,574
Stockholders’ equity (deficit)
Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding as of March 31, 2024; no shares authorized, issued, and outstanding as of December 31, 2023		—			—
Common stock, $0.00001 par value; 490,000,000 and 140,492,016 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 43,115,244 and 1,250,103 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		—			—
Additional paid-in capital		523,728			4,642
Accumulated other comprehensive income (loss)		(1	)		4
Accumulated deficit		(162,736	)		(136,043	)
Total stockholders’ equity (deficit)		360,991			(131,397	)
Total liabilities, redeemable convertible preferred stock and   stockholders’ equity (deficit)	$	389,984		$	75,195